Albion Financial Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Albion Financial Group’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.99K	Hold	3,043	–	–	﹤0.01%	503
2026 Q1	$4.81K	Hold	3,043	–	–	﹤0.01%	482
2025 Q4	$5.08K	Hold	3,043	–	–	﹤0.01%	465
2025 Q3	$5.14K	Hold	3,043	–	–	﹤0.01%	449
2025 Q2	$2.76K	Hold	3,043	–	–	﹤0.01%	461
2025 Q1	$1.38K	Hold	3,043	–	–	﹤0.01%	510
2024 Q4	$1.53K	Hold	3,043	–	–	﹤0.01%	572
2024 Q3	$2.75K	Hold	3,043	–	–	﹤0.01%	408
2024 Q2	$3.04K	Hold	3,043	–	–	﹤0.01%	403
2024 Q1	$4.5K	Hold	3,043	–	–	﹤0.01%	363
2023 Q4	$3.32K	Hold	3,043	–	–	﹤0.01%	370
2023 Q3	$3.59K	Hold	3,043	–	–	﹤0.01%	346
2023 Q2	$4.29K	Hold	3,043	–	–	﹤0.01%	343
2023 Q1	$4.57K	Hold	3,043	–	–	﹤0.01%	339
2022 Q4	$3.56K	Hold	3,043	–	–	﹤0.01%	354
2022 Q3	$3K	Hold	3,043	–	–	﹤0.01%	374
2022 Q2	$5K	Hold	3,043	–	–	﹤0.01%	356
2022 Q1	$5K	Hold	3,043	–	–	﹤0.01%	413
2021 Q4	$7K	Hold	3,043	–	–	﹤0.01%	429
2021 Q3	$8K	Hold	3,043	–	–	﹤0.01%	392
2021 Q2	$9K	Buy	+3,043	New	+$7.87K	﹤0.01%	381
2020 Q4	$5K	Buy	+3,043	New	+$4.25K	﹤0.01%	383
2015 Q4	–	Sell	-28,603	Closed	-$69K	–	176
2015 Q3	$69K	Hold	28,603	–	–	0.01%	175
2015 Q2	$84K	Hold	28,603	–	–	0.01%	180
2015 Q1	$115K	Hold	28,603	–	–	0.02%	173
2014 Q4	$86K	Hold	28,603	–	–	0.01%	174
2014 Q3	$72K	Hold	28,603	–	–	0.01%	177
2014 Q2	$70K	Hold	28,603	–	–	0.01%	188
2014 Q1	$76K	Hold	28,603	–	–	0.01%	185
2013 Q4	$83K	Hold	28,603	–	–	0.02%	168
2013 Q3	$88K	Hold	28,603	–	–	0.02%	168
2013 Q2	$91K	Buy	+28,603	New	+$91.6K	0.02%	154

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Albion Financial Group's LCTX Position: Q2 2026 in Review

Albion Financial Group held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 3,043 shares worth $3.99K. The position accounts for ﹤0.01% of the portfolio, ranked #503.

Albion Financial Group first reported a position in LCTX in Q2 2013 and has held it in 32 quarters since. The position peaked at $115K in Q1 2015. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Albion Financial Group held 3,043 shares of Lineage Cell Therapeutics worth $3.99K as of Q2 2026.
Albion Financial Group left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Albion Financial Group's portfolio in Q2 2026, its #503 holding.
Albion Financial Group first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 32 quarters since.
Albion Financial Group's Lineage Cell Therapeutics position peaked at $115K in Q1 2015.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Albion Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.